NewAmsterdam Pharma Company N.V (NAMS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $30.28: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 15.00; Below-average business quality; Negative price momentum.
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company developing obicetrapib, an oral CETP inhibitor for LDL-C lowering in cardiovascular disease patients. The company has no approved products and generates no product revenue; it is funded through equity and operates... Read more
Sell if holding. Engine safety override at $30.28: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 15.00; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.1/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-10Recent Developments — NewAmsterdam Pharma Company N.V
Latest news
- NEWS Monster Beverage, Westrock Coffee, Himax Technologies And Other Big Stocks Moving Higher On Friday — benzinga May 8, 2026 neutral
- NEWS NewAmsterdam Pharma Q1 EPS $(0.40) Beats $(0.47) Estimate, Sales $3.040M Beat $936.364K Estimate — benzinga May 7, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineobicetrapib10-K Item 1A: 'We are dependent on the success of our only product candidate, obicetrapib, and cannot guarantee that obicetrapib will successfully complete clinical development, receive regulatory approval'
Material Events(8-K, last 90d)
- 2026-04-24Item 5.02MEDIUMLouise Kooij, Chief Accounting Officer, agreed to depart effective August 31, 2026. Separation agreement includes 12 months base salary and pro-rated bonus. No successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $30.28: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 15.00; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $28.72. Score 5.1/10, moderate confidence.
Take-profit target: $43.39 (+42.8% upside). Prior stop was $28.72. Stop-loss: $28.72.
Concentration risk — Pipeline: obicetrapib; Quality below floor (3.4 < 4.0).
NewAmsterdam Pharma Company N.V trades at a P/E of N/A (forward -23.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
22 analysts cover NAMS with a consensus score of 4.3/5. Average price target: $50.
What does NewAmsterdam Pharma Company N.V do?NewAmsterdam Pharma is a clinical-stage biopharmaceutical company developing obicetrapib, an oral CETP inhibitor for...
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company developing obicetrapib, an oral CETP inhibitor for LDL-C lowering in cardiovascular disease patients. The company has no approved products and generates no product revenue; it is funded through equity and operates at a net loss ($203.8M in 2025).